BPH Global Ltd (ASX:BP8)
Australia · Delayed Price · Currency is AUD 0.0010
0.00 (0.00%)
Sep 7, 2026, 9:59 AM AEST
BPH Global Revenue
In the fiscal year ending June 30, 2026, BPH Global had annual revenue of 3.44M AUD with 877.51% growth. BPH Global had revenue of 2.07M in the half year ending June 30, 2026, with 1,781.43% growth.
Revenue
3.44M
Revenue Growth
+877.51%
P/S Ratio
0.68
Revenue / Employee
111.11K
Employees
31
Market Cap
2.35M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 3.44M | 3.09M | 877.51% |
| Jun 30, 2025 | 352.38K | 242.41K | 220.44% |
| Jun 30, 2024 | 109.97K | 109.63K | 32,338.05% |
| Jun 30, 2023 | 339.00 | -493.67K | -99.93% |
| Jun 30, 2022 | 494.01K | -8.00M | -94.19% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vitura Health | 131.16M |
| ECS Botanics Holdings | 21.02M |
| IDT Australia | 20.38M |
| Elixinol Wellness | 15.90M |
| Epsilon Healthcare | 13.58M |
| Peak Processing | 12.51M |
| Cann Group | 9.65M |
| Syntara | 6.93M |